Karen Uhlmann
Founder at OMEICOS Therapeutics GmbH
Karen Uhlmann active positions
| Companies | Position | Start | End |
|---|---|---|---|
OMEICOS Therapeutics GmbH
 OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Chief Operating Officer | 2012-12-31 | - |
| Founder | 2012-12-31 | - | |
| General Counsel | 2012-12-31 | - |
Career history of Karen Uhlmann
Training of Karen Uhlmann
| Freie Universität Berlin | Graduate Degree |
| Humboldt-Universität zu Berlin | Doctorate Degree |
Statistics
International
| Germany | 4 |
Operational
| Chief Operating Officer | 1 |
| Founder | 1 |
| General Counsel | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Health Technology |
- Stock Market
- Insiders
- Karen Uhlmann
- Experience
